Short Interest in GH Research PLC (NASDAQ:GHRS) Grows By 6.0%

GH Research PLC (NASDAQ:GHRS) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 1,600,000 shares, an increase of 6.0% from the September 15th total of 1,510,000 shares. Based on an average daily volume of 39,800 shares, the short-interest ratio is currently 40.2 days. Currently, 5.3% of the shares of the stock are sold short.

GH Research Stock Up 9.0 %

Shares of GHRS stock traded up $0.64 during trading hours on Wednesday, reaching $7.74. 101,114 shares of the stock traded hands, compared to its average volume of 81,278. The firm has a market capitalization of $402.70 million, a PE ratio of -12.48 and a beta of 0.79. GH Research has a 1-year low of $5.05 and a 1-year high of $14.99. The business has a fifty day moving average price of $8.61 and a 200 day moving average price of $10.78.

GH Research (NASDAQ:GHRS) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. Research analysts expect that GH Research will post -0.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its stake in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the quarter. GH Research accounts for 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th largest position. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on GHRS. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reiterated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).